DIRS.INFO The most relevant business & tech news

☆ The S&P 500 tops a record high that ‘clears the charts’ of resistance ahead of a week of earnings, inflation data
▼ + stars: | 2024-01-19 | by ( Sarah Min | ) www.cnbc.com time to read: +6 min

The S & P 500 rallied more than 1% on Friday, above both its closing and intraday records that it last reached in January 2022. "Meaning that when a major index like the S & P 500, like the Nasdaq 100, reaches a new all time high, what it does is, it clears the charts of resistance." For 2024, Wald anticipates the S & P 500 will end the year at the 5,400 level, representing a roughly 12% rise from Friday's close of 4,839.81. Inflation data, earnings ahead Next week will also bring the Fed's preferred inflation gauge for December, which is expected to confirm the recent trend of easing inflation. Leading Indicators Tuesday Jan. 23 10 a.m. Richmond Fed Index (January) Earnings: General Electric , Synchrony Financial , D.R.

Persons: it's, Katie Stockton, we've, Oppenheimer's Ari Wald, Wald, Dow Jones, That's, Dave Sekera, Sekera, Jan, Johnson, Lockheed Martin, Lockheed Martin Wednesday Jan, Kimberly, Clark, Northrop Organizations: Fed, Nasdaq, Morningstar Research Services, Richmond Fed, Synchrony, Raytheon Technologies, Verizon Communications, Halliburton, Johnson, Procter, Gamble, Lockheed, Lockheed Martin Wednesday, PMI, SA, PMI Manufacturing SA, PMI Services SA, Abbott Laboratories, Chicago, New, . Kansas City Fed Manufacturing, Northrop Grumman, Southwest Airlines, American Airlines, Comcast, PCE, Norfolk, American, CNBC Locations: Stockton, U.S, Horton, Freeport, McMoRan, . Kansas

☆ Cramer's week ahead: Earnings from Procter & Gamble, Tesla, Lockheed Martin
▼ + stars: | 2024-01-19 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Friday told investors to gear up for a "fast and furious" slew of earnings reports next week that could lead to some profit-taking, including Procter & Gamble , Tesla and Lockheed Martin . Only if we still have plenty of people out there bad-mouthing the market and calling it dangerous and perilous," Cramer said. Tuesday is one of the busiest days of the week, with reports from Procter & Gamble , Verizon , 3M , Johnson & Johnson , RTX , Lockheed Martin , D.R. Cramer predicted Verizon will do well, but Procter & Gamble may not see a blowout quarter, perhaps creating a buying opportunity. He'll be waiting to hear about an increased defense budget from Lockheed Martin and said D.R.

Persons: CNBC's Jim Cramer, Tesla, Lockheed Martin, Cramer, Johnson, D.R, He'll, Horton, he'll, Williams Organizations: Procter & Gamble, Lockheed, United Airlines, Logitech, Verizon, Johnson, General Electric, Netflix, Procter, Gamble, Abbott Laboratories, Tesla, Lam Research, IBM, Union Pacific, Intel, Sherwin, PayPal, American Express, Norfolk Southern, Federal Reserve Locations: RTX, Horton, Colgate

☆ Why we like health-care stocks in 2024 despite their spotty record in presidential election years
▼ + stars: | 2024-01-18 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +11 min

The S & P 500 Health Care Sector index has outperformed the broader S & P 500 in just three of the past eight presidential election years dating back to 1992, according to FactSet data. So far in 2024, health care has been the best-performing sector in the S & P 500, climbing roughly 2%. .GSPHC .SPX YTD mountain Health care sector vs. S & P 500 YTD It's way too early for any grand predictions with Election Day 2024 about 10 months away. Nevertheless, we see attractive fundamentals in the year ahead for a host of health-care stocks, giving us the confidence to own Lilly, GE Healthcare and Danaher despite what history says about the group in presidential election years. After a strong 2022 for health care in a terrible overall market, investors last year placed a lower emphasis on the defensive characteristics of health care.

Persons: —, that's, Eli Lilly, Lilly, Jim Cramer, Jim, Sen, Bernie Sanders of, Joe Biden, Sanders, would've, Damien Conover, Conover, Biden, Eli Lilly's, Morningstar, Amgen, Morningstar's Conover, Lilly's donanemab, Humana, Bausch, Jim Cramer's, Frederick Florin Organizations: Health, GE Healthcare, Abbott Laboratories, Amgen, Novartis, Walgreens Boots Alliance, JPMorgan Healthcare Conference, Democratic, Morningstar, CNBC, Horizon Therapeutics, Novo Nordisk, Federal Reserve, General Electric, Medicare, Humana, UnitedHealth Group, Investors, AFP, Getty Locations: San Francisco, U.S, Bernie Sanders of Vermont, Canadian, Fegersheim, France

☆ 'A trove of rebound opportunities': Strategists turn bullish on biotech and more, picking top stocks
▼ + stars: | 2024-01-17 | by ( Weizhen Tan | ) www.cnbc.com time to read: +4 min

2023 wasn't a good year for the health-care sector, but some investors expect it to make a comeback this year — highlighting biotech and medical tech as areas to watch. But now, Citi believes that "astute investors may find themselves with a trove of rebound opportunities." Citi's top picks in biotech include Biomea Fusion , Alnylam Pharmaceuticals , and Immunovant . Jared Holz, health-care sector strategist at Mizuho Securities Americas, named biotech firm Biogen as one of his top trading ideas for 2024. "Biotech has commanded everyone's attention, but the recovery of many best-in-class medical device companies post the GLP-1 selloff has been remarkable," Orton said.

Persons: There's, Jared Holz, Biogen, Trent, medtech, Matt Orton, Orton Organizations: Citi Global Wealth Investments, U.S . Healthcare, Citi, Biomea, Alnylam Pharmaceuticals, Mizuho Securities Americas, Biogen, medtech, Raymond James Investment Management, Medical, Biotech, Abbott Laboratories Locations: U.S, Alphinity, medtech

☆ AI, wearables and more — these markets are booming as the world ages. The pros share 4 stock picks
▼ + stars: | 2023-12-27 | by ( Weizhen Tan | ) www.cnbc.com time to read: +6 min

"The aging population discussion in recent years has mostly revolved around future challenges to labor productivity and its economic growth implications," he said. AI, robotics and wearables The aging population stands to gain significantly from breakthroughs in robotics powered by artificial intelligence, according to Afzal. Arelis Agosto, research analyst at Global X ETFs, said wearables technology is one interesting area to invest in for the aging theme. "We view self-sustaining monitoring and therapeutic systems as the future of patient care, though it is particularly beneficial for elderly patients," Agosto said. Global X ETFs, a fund management company, offers a way to tap the aging theme through its Aging Population ETF.

Persons: Shams Afzal, There's, Afzal, Stryker, Dani Saurymper, Saurymper, Arelis Agosto, Agosto Organizations: Carnegie Investment, CNBC Pro, Stryker, EU, Longevity, Global, Carnegie, Abbott Laboratories, Agosto Locations: U.S, GLP, Agosto

☆ Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
▼ + stars: | 2023-12-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

That includes Novo Nordisk 's Wegovy and diabetes treatment Ozempic as well as Eli Lilly 's diabetes drug Mounjaro. They have all skyrocketed in popularity — and slipped into shortages — over the last year for safely and successfully causing significant weight loss. But before the current weight loss industry gold rush, the path to treating obesity was strewn with failures dating back decades. In its full-year 2019 earnings, Eisai reported that Lorcaserin had sales of $28.1 million in the U.S. for the year. Sanofi's rimonabantAn obesity drug called rimonabant from Sanofi and Aventis was withdrawn from all markets in 2008 due to the risk of serious psychiatric problems, including suicide.

Persons: Eli Lilly, drugmakers, lorcaserin, Eisai, Lorcaserin Organizations: Getty, Pfizer, Novo Nordisk, U.S, Drug Administration, FDA, Aventis, Abbott Laboratories Locations: U.S, Sanofi

☆ Cramer's Lightning Round: 'Stay away' from Catalent
▼ + stars: | 2023-11-29 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Vishay Intertechnology's year-to-date stock performance. Stock Chart Icon Stock chart icon Abbott Laboratories' year-to-date stock performance. Stock Chart Icon Stock chart icon Anheuser-Busch's year-to-date stock performance. Stock Chart Icon Stock chart icon Catalent's year-to-date stock performance. Stock Chart Icon Stock chart icon Moelis & Company's year-to-date stock performance.

Persons: Vishay, you've, Lads, Jim Cramer's Organizations: Abbott Laboratories, Anheuser, Moelis Locations: Catalent

☆ Medical device maker Medtronic raises fiscal 2024 profit view
▼ + stars: | 2023-11-21 | by ( ) www.reuters.com time to read: +1 min

Medtronic Plc logo is seen displayed in this illustration taken, April 10, 2023. Medtronic joins medical device makers including Abbott Laboratories (ABT.N) and Boston Scientific(BSX.N) that have benefited from soaring demand for non-urgent surgeries. It now expects profit to be between $5.13 per share and $5.19 per share for the fiscal year 2024, above the range of $5.08 per share to $5.16 per share expected previously. On an adjusted basis, the Dublin-based company reported a profit of $1.25 per share for the second quarter, above analysts' average estimate of $1.18 per share, according to LSEG data. Reporting by Khushi Mandowara and Christy Santhosh in Bengaluru; Editing by Pooja DesaiOur Standards: The Thomson Reuters Trust Principles.

Persons: Dado Ruvic, Medtronic, Khushi Mandowara, Christy Santhosh, Pooja Desai Organizations: REUTERS, Abbott, Abbott Laboratories, Boston, Thomson Locations: Dublin, Bengaluru

☆ Can you hack your brain? These companies are driving innovation in the field of brain stimulation
▼ + stars: | 2023-11-21 | by ( Pia Singh | ) www.cnbc.com time to read: +12 min

These forms of deep brain stimulation require a surgical procedure during which electrodes — which generate electrical impulses to control any abnormal brain activity — are implanted into certain areas of the brain. With enough advancement in the field, doctors expect brain stimulation techniques for both severe disorders and health-and-wellness purposes will ultimately become noninvasive. Three major players There are only three companies with FDA-approved deep brain stimulation, or DBS, treatments: Medtronic , Abbott Laboratories and Boston Scientific . The spinal cord stimulation, or SCS, business is a hotbed of innovation right now, deep brain stimulation also is a key area." There is still plenty of doubt, however, about the efficacy of at-home brain stimulation devices, which offer a less direct approach to brain stimulation and don't always require FDA oversight.

Persons: —, Bernstein, Lee Hambright, Hambright, Ali Rezai, Medtronic, Abbott, Rezai, Morningstar, Debbie Wang, Wang, Elon Musk, it's Elon Musk's, Casey Halpern, it's, Halpern, Taiwan's Organizations: Drug Administration, FDA, Abbott Laboratories, Boston, Rockefeller Neuroscience, West Virginia University, American Neuromodulation Society, Boston Scientific, DBS, FactSet, Neuroscience, BCI, University of Pennsylvania, TMS Locations: neuromodulation

☆ Medical device stocks rise in relief after Wegovy heart benefits data
▼ + stars: | 2023-11-13 | by ( ) www.reuters.com time to read: +2 min

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. To be sure, the full results presented on Saturday at a major medical meeting gave analysts even more confidence in the heart protective benefits of the hugely popular drug. That lifted shares of Penumbra (PEN.N), which makes devices used in surgeries for stroke patients, 13% in morning trading. Its shares have tumbled about 28% as of last close since Novo in August said Wegovy had also shown a clear cardiovascular benefit. "The full detailed results ... do not shift our outlook that MedTech device stocks appear broadly oversold," said Leerink analyst Mike Kratky.

Persons: Victoria Klesty, Wegovy, Baird, Jeff Johnson, Eli Lilly's, Mike Kratky, Leroy Leo, Medha Singh, Sriraj Organizations: REUTERS, Novo, Devices, Abbott Laboratories, Thomson Locations: Oslo, Norway, Victoria, MedTech, Penumbra, Novo, Friday's, Bengaluru

☆ Corporate America weighs business impact of new weight-loss drugs
▼ + stars: | 2023-11-08 | by ( ) www.reuters.com time to read: +4 min

Walmart (WMT.N) expects revenues from its health and wellness products to increase in the second half of the year, mainly due to the popularity of weight-loss drugs. PepsiCo (PEP.O) Chief Financial Officer Hugh Johnston has said the company is "not seeing any impact" yet from the popularity of weight-loss drugs. Coca-Cola (KO.N) CEO James Quincey said the company was monitoring what impact, if any weight-loss drugs will have. Abbott CEO Robert Ford has said diabetes patients could end up using glucose monitors with the weight-loss drugs in the long term. DRUG DISTRIBUTORSCencora (COR.N), formerly called AmerisourceBergen, Cardinal Health (CAH.N) and McKesson (MCK.N) have flagged potential boost to revenues this year owing to the growing demand for weight-loss drugs.

Persons: Victoria Klesty, Eli Lilly's, Eli Lilly's Zepbound, Hugh Johnston, James Quincey, Michele Buck, Dr Pepper, Robert Gamgort, Johnson, Joseph Wolk, Robert Ford, Michael Farrell, Bhanvi Satija, Ananya Mariam Rajesh, Mrigank Dhaniwala, Arun Koyyur Organizations: REUTERS, U.S . Food, Drug Administration, Walmart, PepsiCo, J, Abbott Laboratories, Insulet Corp, Boston Scientific, Cardinal Health, Thomson Locations: Oslo, Norway, Victoria, U.S, GLP, Bengaluru

☆ Medical device maker Zimmer cuts revenue growth forecast as profit beats
▼ + stars: | 2023-11-07 | by ( ) www.reuters.com time to read: +2 min

Sales at Zimmer's knees unit rose 7.5% to $706.3 million, compared to analysts' estimate of $702.9 million. That helped cushion a miss at its hips unit, where sales of $465.3 million compared with estimates of $481.7 million. The Indiana-based company's third-quarter revenue rose 5% to $1.75 billion, in line with analysts' average estimates. Zimmer had said earlier that it expects second- and third-quarter revenue to be a "little bit lighter" compared to the first quarter. The hip and knee implant maker cut its full-year reported revenue forecast to a growth of 6% to 6.5% from 6.5% to 7.0% earlier while backing its full-year profit forecast of $7.47 to $7.57 per share.

Persons: Zimmer Biomet, Moritz Hager, Zimmer, Johnson, Ivan Tornos, Christy Santhosh, Sriraj Organizations: REUTERS, Zimmer Biomet Holdings, Laboratories, Boston, Thomson Locations: Winterthur, Switzerland, Indiana, Bengaluru

☆ GE HealthCare beats quarterly profit estimates on imaging device demand
▼ + stars: | 2023-10-31 | by ( ) www.reuters.com time to read: +2 min

A logo is displayed on a GE digital anesthesia carestation as U.S. Vice President Mike Pence (not pictured) visits a GE Healthcare manufacturing facility during the global coronavirus disease (COVID-19) outbreak in Madison, Wisconsin, U.S. April 21, 2020. Larger peer Abbott Laboratories (ABT.N) also topped its quarterly profit estimates, aided by a recovery in sales of its medical devices such as heart valves and pacemakers. In the previous quarter, GE HealthCare had said that Alzheimer's-related testing would help drive demand for its imaging equipment at hospitals and medical centers next year. $2.64 billion of the sales came from imaging devices, in line with estimates. On an adjusted basis, GE HealthCare earned 99 cents per share, above LSEG estimates of 90 cents.

Persons: Mike Pence, Daniel Acker, Christy Santhosh, Maju Samuel Organizations: GE, GE Healthcare, REUTERS, GE HealthCare Technologies Inc, Abbott Laboratories, GE HealthCare, Thomson Locations: Madison , Wisconsin, U.S, COVID, United States, Bengaluru

One death this year and more than two dozen reports of injuries since 2018 may be tied to the supplements, FDA officials said in a statement. No probiotic products have been approved as a drug or treatment for babies, the FDA said. FDA officials in September said Evivo with MCT Oil, a probiotic made by Infinant Health of Norwalk, Connecticut, led to the death of a premature infant this year. Infinant Health officials said in statement that the firm voluntarily recalled and discontinued the product. Probiotic supplements may be used to prevent necrotizing enterocolitis, a dangerous infection affecting premature infants that inflames and kills intestinal tissue.

Persons: necrotizing, Matthew Perrone Organizations: . Food, Drug Administration, FDA, Abbott Laboratories, Abbott, MCT, Infinant, Infinant Health, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: Illinois, Norwalk , Connecticut, Washington

☆ As Ozempic and Wegovy take off, this tech startup just raised $20 million to tackle weight loss with data
▼ + stars: | 2023-10-24 | by ( Ashley Capoot | ) www.cnbc.com time to read: +6 min

Weight loss has always been big business, but it's exploded of late due to surging demand for Ozempic, Wegovy and other new diabetes and obesity drugs. "Whether you have five pounds to lose or 100, we want to make sure we're able to help everybody," Sharam Fouladgar-Mercer, Signos' co-founder and CEO, told CNBC in an interview. Fouladgar-Mercer said he created the company in 2018 partly because of his own struggle to manage weight throughout his life. Users can also integrate sleep data, heart rate data, and exercise data from their Apple Watch to personalize their profile even more. Fouladgar-Mercer said Signos can work well alongside Ozempic and Wegovy from Novo Nordisk and other GLP-1 treatments.

Persons: Signos, Mercer, it's, It's, GLP Organizations: Cheyenne Ventures, GV, Google Ventures, Dexcom Ventures, CNBC, Signos, U.S . Food, Drug Administration, Apple Watch, Abbott Laboratories, U.S, Novo Nordisk, Nordisk's Locations: Mercer, Novo, Europe, Fouladgar, America

☆ Corporate America weighs risks of the Ozempic effect
▼ + stars: | 2023-10-19 | by ( ) www.reuters.com time to read: +3 min

Walmart (WMT.N) expects revenues from its health and wellness products to increase in the second half of the year, mainly due to the popularity of weight-loss drugs. PepsiCo (PEP.O) Chief Financial Officer Hugh Johnston has said the company is "not seeing any impact" yet from the popularity of weight-loss drugs. Abbott Laboratories (ABT.N), which makes glucose monitoring products, has said that the market was overestimating the impact to its sales from growing popularity of the drugs. Abbott CEO Robert Ford has said that diabetes patients could end up using glucose monitors with the weight-loss drugs in the long term. DRUG DISTRIBUTORSCencora (COR.N), formerly called AmerisourceBergen, Cardinal Health (CAH.N) and McKesson (MCK.N) have flagged potential boost to revenues this year owing to the growing demand for weight-loss drugs.

Persons: George Frey, Eli Lilly's, Hugh Johnston, Johnson, Joseph Wolk, Robert Ford, Bhanvi, Mrigank Organizations: Novo Nordisk, Pharmacy, REUTERS, Walmart, PepsiCo, Abbott Laboratories, Insulet Corp, Cardinal Health, Thomson Locations: Provo , Utah, U.S, Bengaluru

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., September 26, 2023. Demand for safe-haven assets sent gold prices to a more than two-month high, up over 1%, while the U.S. dollar also strengthened. Stronger crude prices pushed energy stocks (.SPNY) 1% higher, while industrials (.SPLRCI) and materials (.SPLRCM) led the decline in major S&P 500 sectors. Declining issues outnumbered advancers by a 3.90-to-1 ratio on the NYSE and by a 2.69-to-1 ratio on the Nasdaq. The S&P index recorded 11 new 52-week highs and 14 new lows, while the Nasdaq recorded 20 new highs and 149 new lows.

Persons: Brendan McDermid, Morgan Stanley, Joe Biden, Biden, Treasuries aren't, Brian Jacobsen, homebuilding, Chris Giamo, Morgan Stanley's, New York's John Williams, Christopher Waller, Michelle Bowman, Jerome Powell's, Patrick Harker, Ankika Biswas, Shashwat Chauhan, Sruthi Shankar, Arun Koyyur, Vinay Dwivedi Organizations: New York Stock Exchange, REUTERS, Tuesday United Airlines, Dow, Nasdaq, U.S ., Annex Wealth Management, Federal Reserve, TD Bank, Abbott Laboratories, Consumer, Procter, Gamble, Tesla, Netflix, . Philadelphia Fed, Wall Street Journal, Dow Jones, Nvidia, Biden, China . United Airlines Holdings, NYSE, Thomson Locations: New York City, U.S, Israel, Gaza, New, China, Bengaluru

REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsOct 18 (Reuters) - Abbott Laboratories (ABT.N) said the market was overestimating the hit to sales of its glucose monitoring products from growing popularity of new diabetes drugs, adding the treatments could end up boosting sales of the medical device maker. The company's shares have dropped 16% this year, mainly on concerns that new GLP-1 diabetes drugs such as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro could eat into the sales of its continuous glucose monitoring (CGM) devices. Hurdles in health insurance reimbursement and pricing could, however, keep market growth for GLP-1 drugs limited to a small number of patients in the near term, Abbott CEO Robert Ford said on Wednesday. Third-quarter sales of FreeStyle Libre, Abbott's CGM device used by diabetes patients, jumped 30.5% to $1.4 billion, lifting Abbott's shares 3% in morning trade. The numbers helped Abbott's medical device sales that stood at $4.25 billion, beating analysts' estimates of $4.16 billion, according to LSEG data.

Persons: Brendan McDermid, Nordisk's Ozempic, Eli Lilly's, Abbott, Robert Ford, Ford, Vijay Kumar, Pratik Jain, Leroy Leo, Anil D'Silva, Shounak Dasgupta, Shinjini Organizations: Abbott, New York Stock Exchange, REUTERS, Abbott Laboratories, Nordisk's, Thomson Locations: New York City, U.S, GLP, Bengaluru

☆ Abbott profit beats on strong sales of medical devices, diagnostics
▼ + stars: | 2023-10-18 | by ( ) www.reuters.com time to read: +1 min

Abbott Laboratories logo is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, U.S., October 18, 2021. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsOct 18 (Reuters) - Abbott Laboratories (ABT.N) on Wednesday tightened its profit forecast for the year after beating estimates for third-quarter earnings on strong demand for its medical devices and diagnostics products. The company is seeing a recovery in sales of its medical devices such as heart valve devices and pacemakers as more older people opt for surgeries that were put off due to the pandemic. Abbott posted a near 17% rise in quarterly sales of its medical devices to $4.25 billion, beating analysts' estimates of $4.16 billion. Excluding items, Abbott earned $1.14 per share, above analysts' estimates of $1.10 per share, according to LSEG data.

Persons: Brendan McDermid, Abbott, Nordisk's Ozempic, Eli Lilly's, Mounjaro, Pratik Jain, Leroy Leo, Anil D'Silva Organizations: Abbott, New York Stock Exchange, REUTERS, Abbott Laboratories, Libre, Nordisk's, Thomson Locations: New York City, U.S, Bengaluru

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., September 26, 2023. On the earnings front, consumer goods maker Procter & Gamble (PG.N) edged up 0.2% after its quarterly sales topped market expectations. EV maker Tesla (TSLA.O) and streaming services company Netflix (NFLX.O) are scheduled to report quarterly results after market close. ET, Dow e-minis were down 93 points, or 0.27%, S&P 500 e-minis were down 18.5 points, or 0.42%, and Nasdaq 100 e-minis were down 88.25 points, or 0.58%. Travelers Companies (TRV.N) reported a 14% fall in quarterly profit.

Persons: Brendan McDermid, Joe Biden, Morgan Stanley, New York's John Williams, Governors Christopher Waller, Michelle Bowman, Jerome Powell's, Powell, Patrick Harker, Neel Kashkari, Ankika Biswas, Shashwat Chauhan, Arun Koyyur, Vinay Dwivedi Organizations: New York Stock Exchange, REUTERS, United Airlines, Dow, Nasdaq, U.S, Chevron, Exxon Mobil, Occidental Petroleum, Treasury, Procter, Gamble, Abbott Laboratories, Tesla, Netflix, Federal Reserve, Governors, Generale, Philadelphia Fed, Wall Street Journal, Minneapolis, Dow e, Nvidia, Biden, China . United Airlines Holdings, Rivals American Airlines, Delta Air Lines, Interactive, Travelers Companies, Thomson Locations: New York City, U.S, United, Gaza, Israel, New, China, Bengaluru

☆ The top 10 things to watch in the stock market Wednesday
▼ + stars: | 2023-10-18 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

U.S. stock are under pressure in premarket trading Wednesday, with S & P 500 futures down 0.47%. Revenues at its wealth management division rise 4.6% but fall short of analysts' forecasts, sending shares tumbling by 2.6% in premarket trading. Morgan Stanley reduces its price target to $600 a share, down from $630, while Citi lowers to $575 a share, from $630. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Morgan Stanley, Jefferies, Goldman Sachs, Wells Fargo, Sherwin, Williams, Jim Cramer's, Jim Cramer, Jim Organizations: Treasury, West Texas, Club, Procter, Gamble, Abbott Laboratories, Citi, Nvidia, Visa, Mastercard, Journal, Coterra Energy, Occidental Petroleum, Antero Resources, Starbucks, JPMorgan, Meta, Bank of America, Dow Inc, Huntsman Corp, LyondellBasell Industries, Albemarle, Westlake Corporation, Jim Cramer's Charitable, CNBC Locations: China

☆ Morning Bid: US growth topping China as megacaps report
▼ + stars: | 2023-10-18 | by ( ) www.reuters.com time to read: +5 min

A street sign for Wall Street hangs in front of the New York Stock Exchange May 8, 2013. The combination of high-pressure growth and U.S. crude oil prices back up to their highest in two weeks has re-ignited inflation concerns. And with a 20-year Treasury bond auction also due later in the day, bond markets are back running scared. Two-year Treasury yields hit their highest since 2006 on Tuesday at 5.24% and held most of those gains overnight - while 20-year yields are hovering around 5.2% as well. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Lucas Jackson, Mike Dolan, Joe Biden's, megacaps Tesla, Jerome Powell, China's, Republican Jim Jordan, Morgan Stanley, Kinder Morgan, Elevance, Joe Biden, Christopher Waller, Lisa Cook, Michelle Bowman, John Williams, Patrick Harker, Toby Chopra Organizations: New York Stock Exchange, REUTERS, Federal Reserve, Atlanta, Netflix, Atlanta Fed, Fed, Treasury, Bank of England's, Wall St, Republican, Procter, Gamble, Abbott Laboratories, Northern Trust, Nasdaq, Citizens Financial, US Bancorp, Zions Bancorp, Discover, Lam Research, Alcoa, Steel Dynamics, Federal, New York Fed, Philadelphia Fed, Graphics Retail, Thomson, Reuters Locations: U.S, Gaza, Israel, trepidation, United States, Britain, Wall, Stocks, Asia, Europe, Northern, POPG, Equifax

☆ Stocks making the biggest moves midday: United Airlines, Nvidia, Morgan Stanley and more
▼ + stars: | 2023-10-18 | by ( Samantha Subin | ) www.cnbc.com time to read: +4 min

Late Tuesday, the company posted third-quarter results that fell short of Wall Street's expectations on the top and bottom lines. The company posted third-quarter adjusted earnings of $1.55 per share on adjusted revenue of $1.14 billion. Abbott posted earnings of $1.14 per share, excluding items, beating analysts' estimates by 4 cents a share, according to FactSet. It posted revenue of $2.69 billion, which was not immediately comparable to consensus estimates. It posted revenue of $771.0 million, lower than the consensus estimate of $784.3 million, according to FactSet.

Persons: Morgan Stanley, . Hunt, Gamble — Procter, LSEG, Abbott, Michael Happe, —, Yun Li, Sarah Min, Tanaya, Hakyung Kim, Pia Singh Organizations: United Airlines —, United Airlines, Nvidia, U.S, Citi, Devices, Marvell Technology, Hunt Transport Services, LSEG, Interactive, Procter, Gamble, Abbott, Financial, Citizens Financial, State, FactSet, Winnebago Industries, Winnebago, Bancorp, U.S . Bancorp, Bank of America Locations: Tel Aviv, Israel, China, LSEG, Albemarle —

☆ Regional banks are in focus in the week ahead as third-quarter earnings season ramps up
▼ + stars: | 2023-10-13 | by ( Sarah Min | ) www.cnbc.com time to read: +7 min

Regional banks will be in focus in the week ahead as traders head into the thick of third-quarter earnings season. Regional bank earnings are also expected to be a weak point this season. But a closer look into the sector's sub-industries showed that regional banks are anticipated to have tumbled by 15% last quarter. Traders parsing through regional bank earnings will pay special attention to signs of narrowing net interest margins (NIM). Earnings season underway Many investors anticipate that the third-quarter earnings season will be alright.

Persons: Wells, Kumar, FactSet's John Butters, NIM, They'll, JPMorgan Chase, Jamie Dimon, Goldman Sachs, Morgan Stanley, FactSet's Butters, Nancy Tengler, Lauren Goodwin, we'll, Goodwin, Charles Schwab, Lockheed Martin, Goldman, Zions, Kinder Morgan, Lam, McLennan, Philip Morris, Huntington Bancshares, —, Jesse Pound Organizations: Citigroup, JPMorgan Chase, Sri, Kumar, Silicon Valley Bank, Regional Banking, Dow Jones Industrial, JPMorgan, Hamas, Northern Trust, U.S . Bancorp, T Bank, Citizens Financial, Bank of America, Federal Reserve, Companies, Investments, New York Life Investments, Index, Johnson, Bank of New York Mellon, Goldman Sachs Group, Hunt Transport Services, Omnicom, United Airlines Wednesday, Housing, Elevance, Citizens Financial Group, Procter, Gamble, Abbott Laboratories, Discover Financial Services, Las Vegas Sands, PPG Industries, Steel Dynamics, Tesla, Netflix, Lam Research, Philadelphia Fed, Truist, Alaska Air Group, Fifth Third Bancorp, American Airlines Group, Marsh, Philip Morris International, Union, CSX, Comerica, Regions Financial, American Express, Interpublic, Cos Locations: Wells Fargo, Silicon, Ukraine, Israel, J.B, Las Vegas, Philadelphia, Truist Financial, Union Pacific, Freeport, Huntington

☆ Cramer's week ahead: Keep an eye on banks as earnings season kicks off
▼ + stars: | 2023-10-13 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

CNBC's Jim Cramer on Friday told investors what to look out for in the coming week as earnings season kicks off. "The war will continue to overshadow earnings season, but if you keep track of these companies and there's a cessation in the conflict, the market will eventually embrace the good ones," he said. Cramer will also be watching earnings from consumer packaged goods company Procter & Gamble and medical device maker Abbott Laboratories . Cramer also noted there was "suboptimal commentary" surrounding Netflix and Tesla , which will report Wednesday after the market closes. Cramer will also be looking at Friday reports from American Express and oil service giant SLB , formerly known as Schlumberger.

Persons: CNBC's Jim Cramer, Charles Schwab, Goldman Sachs, Cramer, Charles Schwab's, Lockheed Martin, Johnson, Morgan Stanley Organizations: Bank of America, Lockheed, United Airlines, Procter, Gamble, Abbott Laboratories, Netflix, Tesla, Union Pacific, American Express Locations: Israel, KeyCorp, Schlumberger

Search resuls for: "Abbott Laboratories"

25 mentions found